MRI response to neoadjuvant chemotherapy and prognostic implications in breast cancer patients
British Journal of Radiology · 2026
DOI: 10.1093/bjr/tqag023 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Radiology, 2026. Verfasst von Soraia Quaranta Damião und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Imaging, A.C. Camargo Cancer Center, São Paulo 01509-001, SP, Brazil. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Breast Neoplasms, Magnetic Resonance Imaging. Die Arbeit nennt 32 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
To correlate response evaluation after neoadjuvant chemotherapy (NAC), assessed by MRI and pathology, with disease-free survival (DFS) in breast cancer patients, according to immunophenotype.
Methods
Single-centre, IRB-approved retrospective cohort study included consecutive breast cancer patients who underwent NAC and preoperative breast MRI. Pathologic response was evaluated using the residual cancer burden (RCB) system, with pathological complete response (pCR) defined as the absence of invasive carcinoma. Radiological complete response (rCR) was defined as the absence of abnormal enhancement on MRI. The Kaplan-Meier method estimated DFS and Cox regression analysis calculated hazard ratios (HRs).
Results
Five hundred seventy-one patients were included (mean age 46 years, range 26-90). The most common immunophenotype was luminal (42.3%), followed by triple-negative (TNBC, 31.5%) and HER2 overexpressed (26.3%). Radiological and pathological responses were concordant in 71.5%. Overall, 35.2% achieved rCR and 37.5% achieved pCR. Disease-free survival curves did not differ significantly according to radiologic-pathologic response combinations in the luminal or HER2 groups (LogRank P = .505 and P = .257). In the TNBC group, patients without pCR or rCR had significantly worse DFS compared to those achieving either response (LogRank P = .001). Cox regression revealed that TNBC patients with both non-rCR and non-pCR had a markedly higher risk of recurrence or death (HR 7.728; 95% CI 2.696-22.149; P < .001).
Conclusions
Integrating MRI and pathological response assessments after NAC may enhance risk stratification and prognostication, especially in triple-negative breast cancer. Advances in knowledge Patients with both non-rCR and non-pCR have significantly worse DFS, underscoring the prognostic value of combining imaging and pathological findings, particularly in TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Imaging, A.C. Camargo Cancer Center, São Paulo 01509-001, SP, Brazil.
- Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo 01224-001, SP, Brazil.
- Department of Clinical Oncology, A.C. Camargo Cancer Center, São Paulo 01509-001, SP, Brazil.
- Department of Pathology, A.C. Camargo Cancer Center, São Paulo 01509-001, SP, Brazil.
- Department of Breast Surgery, A.C. Camargo Cancer Center, São Paulo 01509-001, SP, Brazil.
ORCID-Profile: Soraia Quaranta Damião
Zitieren
APA
Damião, S. Q., da Cunha, E. F. R., Tavares, M. C., Sanches, S. M., Osorio, C. A. B. T., De Brot, M., Makdissi, F. B., & Bitencourt, A. G. V. (2026). MRI response to neoadjuvant chemotherapy and prognostic implications in breast cancer patients. British Journal of Radiology. https://doi.org/10.1093/bjr/tqag023
Vancouver
Damião SQ, da Cunha EFR, Tavares MC, Sanches SM, Osorio CABT, De Brot M, et al. MRI response to neoadjuvant chemotherapy and prognostic implications in breast cancer patients. British Journal of Radiology. 2026. doi:10.1093/bjr/tqag023
BibTeX
@article{Damio2026,
author = {Damião, Soraia Quaranta and da Cunha, Eduarda Ferreira Rodrigues and Tavares, Monique Celeste and Sanches, Solange Moraes and Osorio, Cynthia Aparecida Bueno de Toledo and De Brot, Marina and Makdissi, Fabiana Baroni and Bitencourt, Almir Galvão Vieira},
title = {MRI response to neoadjuvant chemotherapy and prognostic implications in breast cancer patients},
journal = {British Journal of Radiology},
year = {2026},
doi = {10.1093/bjr/tqag023}
}
EUVIMED